2025, Dec, 22;20(1):126
It is also not usually recommended for infants, children, or adolescents due to limited safety information
Stroke 29 , 830836 (1998)
MAFFT multiple sequence alignment software version 7: improvements in performance and usability
This review aims to summarize the current research progress, elucidate underlying mechanisms, assess the clinical applicability of emerging treatments, and explore potential strategies that may inform future clinical interventions

RELATED: 8 ways to save money on Ozempic How to save on Wegovy for weight loss Wegovy, DailyMed (2024) Ozempic, DailyMed (2025) Rybelsus, DailyMed (2024) Mounjaro, DailyMed (2025) Victoza, DailyMed (2024) Zepbound, DailyMed (2025) Saxenda, DailyMed (2024) Metformin, DailyMed (2020) RYBELSUS (semaglutide) savings and coverage tools for your patients, Novo Nordisk (2024) Chapter 6 Part drugs and formulary requirements, Medicare Prescription Drug Benefit Manual (2016) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity, Lilly (2024) Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
